Novel Oral Pharmaceutical Suspension of Cefdinir Crystal

• US 20070021402A1
• Filed: 09/20/2006
• Published: 01/25/2007
• Est. Priority Date: 11/30/2004
• Status: Active Grant

• Current Assignee: Astellas Pharma Incorporated
• Original Assignee: Astellas Pharma Incorporated
• Inventors: Kitamura, Satoshi, Ohnishi, Naozumi, Deguchi, Shuhei
• Granted Patent: US 7,307,072 B2
• Time in Patent Office: Days
• US Class Current: 514/200
• CPC Class Codes: A61K 31/545 Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. cephalosporins, cefaclor, or cephalexine
• CPC Class Codes: A61K 31/546 containing further heterocyclic rings, e.g. cephalothin
• CPC Class Codes: A61K 9/0095 Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006
• CPC Class Codes: C07D 501/00 Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
• CPC Class Codes: C07D 501/22 with radicals containing only hydrogen and carbon atoms, attached in position 3

Abstract

The present invention relates to a novel oral pharmaceutical suspension of Cefdinir crystal. More specifically, the present invention relates to a novel kit for preparation of an oral pharmaceutical suspension containing crystal form C Cefdinir.

Claims

1. A kit for preparation of an oral pharmaceutical suspension of crystal form C of Cefdinir, wherein said kit comprises:

(a) a composition comprising Cefdinir within a first container; and

(b) a label or a written material indicating that said composition is admixed with pharmaceutically acceptable aqueous carrier prior to administration,

wherein said composition when admixed with said carrier forms an oral pharmaceutical suspension of crystal form C of Cefdinir.

4. The kit of claim 1 wherein said kit further comprises

(c) pharmaceutically acceptable aqueous carrier within a second container.

5. The kit of claim 1 wherein said kit further comprises

(d) a container used for admixing said composition with said pharmaceutically acceptable carrier to form an oral pharmaceutical suspension of said crystal form C.

6. The kit of claim 1 wherein the pharmaceutically acceptable carrier is water.

7. The kit of claim 1, wherein said Cefdinir is admixed with a pharmaceutically acceptable additive or mixture of additives.

2. A kit for preparation of an oral pharmaceutical suspension of crystal form C of Cefdinir, wherein said kit comprises:

(a) a composition comprising a lower hydrate of Cefdinir within a first container; and

(b) a label or a written material indicating that said composition is admixed with pharmaceutically acceptable aqueous carrier prior to administration,

wherein said composition when admixed with said carrier forms an oral pharmaceutical suspension of crystal form C of Cefdinir.

3. The kit of claim 2, wherein the lower hydrate of Cefdinir is monohydrate.

8. The kit of claim 2, wherein the lower hydrate of Cefdinir is admixed with a pharmaceutically acceptable additive or mixture of additives.

9. A method for preparing an oral pharmaceutical suspension comprising crystal form C of Cefdinir, comprising admixing composition containing the lower hydrate of Cefdinir with a pharmaceutically acceptable aqueous carrier.

10. The method of claim 9, wherein the lower hydrate of Cefdinir is monohydrate.